Objective: The objective of this study was to evaluate the effects of Metabolic Syndrome (MetS) and MetS components on tumor size, Fuhrman grade and pathological T stage in renal cell carcinoma (RCC). Materials and Methods: The data of 151 patients who were operated for RCC between January 2010 and April 2018 were retrospectively reviewed according to the he National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and the effects of MetS and its components on tumor size, Fuhrman grade and pathological T stage were comparatively investigated. Results: Of the 151 patients operated for RCC in our clinic, 27.2% had MS, 29.1% had diabetes mellitus (DM), 41% had hypertension (HT), 68.3% had low high-density lipoprotein (HDL), 41% had elevated triglyceride (TGL) elevation, and 27.2% had obesity. It was found that the size of the tumor was statistically significantly increased in the presence of the metabolic criteria examined. There was a statistically significant increase in the Fuhrman grade of the patients with MetS, DM, low HDL, high TGL and obesity. In the presence of clinical conditions such as HT, low HDL and high TGL, there was a statistically significant increase in the pathological T stage. Conclusion: In patients undergoing surgery for RCC, MetS and its components had a statistically significant correlation with tumor size, Fuhrman grade, and pathological stage. If our results are supported by further studies, the correlation between MetS and RCC could be revealed more clearly.